tak 603 has been researched along with Autoimmune Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baba, A; Fukuda, S; Makino, H; Nagai, H; Ohta, Y; Sohda, T; Tsukuda, R | 1 |
| Fukuda, S; Makino, H; Ohta, Y | 1 |
2 other study(ies) available for tak 603 and Autoimmune Disease
| Article | Year |
|---|---|
Immunomodulating and articular protecting activities of a new anti-rheumatic drug, TAK-603.
Topics: Adjuvants, Immunologic; Animals; Antirheumatic Agents; Arthritis, Experimental; Autoimmune Diseases; Cartilage; Cells, Cultured; Cytokines; Dinoprostone; Extracellular Matrix; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Quinolines; Rabbits; Radiography; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Spleen; Triazoles | 1996 |
Reduction of disease causative T-cells in experimental autoimmune disease models by a new antirheumatic drug, TAK-603.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Autoimmune Diseases; CD4-CD8 Ratio; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Lymphocyte Subsets; Male; Quinolines; Rats; Rats, Inbred Lew; Spleen; T-Lymphocytes; Triazoles | 1997 |